Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

• المؤلفون الرئيسيون: Tan, Eng-Huat, Lim, Wan-Teck, Ahn, Myung-Ju, Ng, Quan-Sing, Ahn, Jin Seok, Tan, Daniel Shao-Weng, Sun, Jong-Mu, Han, May, Payumo, Francis C, Mckee, Krista, Yin, Wei, Credi, Marc, Agarwal, Shefali, Jac, Jaroslaw, Park, Keunchil
• مؤلفون آخرون: DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
• التنسيق: مقال
• اللغة: English
• منشور في: WILEY 2022
• الموضوعات: Science & Technology; Life Sciences & Biomedicine; Pharmacology & Pharmacy; ficlatuzumab; NSCLC; gefitinib; lung adenocarcinoma; non-small cell lung cancer; CELL LUNG-CANCER; ADVANCED SOLID TUMORS; FACTOR RECEPTOR; CLINICAL-SIGNIFICANCE; SCATTER-FACTOR; RESISTANCE; MET; MUTATIONS; ERLOTINIB; ADENOCARCINOMA
• الوصول للمادة أونلاين: https://scholarbank.nus.edu.sg/handle/10635/218636

10.1002/cpdd.427